Anorexiants Market Size Worth $1,403.13 Million By 2032 | CAGR: 4.8%

The global anorexiants market size is expected to reach USD 1,403.13 million by 2032, according to a new study by Polaris Market Research. The report “Anorexiants Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Catecholamines, Serotonin); By Route of Administration; By End User; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of the global anorexiants market is highly attributable to the rising consumer interest in weight management, which, in a way, limits appetite. The availability of the class of drugs that suppress appetite is gaining consumers attention as a measure to control calorie intake, creating higher demand. This is driving the pharmaceutical companies to enhance their production capacity. For instance, in February 2024, Novo Holdings unveiled its strategy to acquire Catalent to promote the supply of Wegovy, a weight loss injection, and Ozempic, a diabetic shot, for $16.5 billion.

As the number of people suffering from obesity grows significantly in the future, there will be a huge demand for appetite management drugs in the marketplace during the study period. According to the World Obesity Federation Report 2023, about 4 million people, which is more than 50% of the global population, are estimated to be obese by 2035.

The growing gap between energy consumption and energy spent on physical activities is the building factor leading to the rise in obesity. The increase in the number of people opting for lifestyle modification, with a higher focus on body look due to the growing use of social media, is stimulating the demand for appetite-control medications, such as anorexiants. A 2023 study found that TikTok and Instagram have a significant influence in educating weight management among youth of color in the United States.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/anorexiants-market/request-for-sample

The prevalence of chronic diseases, such as cardiac arrest, type 2 diabetes, and certain cancers, among obese people is grabbing the attention of consumers to consult doctors for treatment, facilitating the need for obese medications, including anorexiants, in healthcare settings. According to the University of Colorado Boulder Research in 2023, obesity increases the risk of death from a minimum of 22% to a maximum of 91%. According to another study, losing weight by 5–10% with diet and physical activities among obese people lowered the risk of developing cardiovascular disease among obese adults.

The growing research studies focusing on the innovation of new medication formulations for the treatment of obesity and weight management are anticipated to showcase significant demand for anorexiants in the world. For instance, in November 2023, the U.S. Food and Drug Administration (FDA) announced the approval of a chronic weight management injection, Zepbound (tirzepatide). In January 2024, Eli Lilly announced its plan to introduce the obesity drug Mounjaro in India in the next year.

Anorexiants Market Report Highlights

• The catecholamines segment is anticipated to witness the highest growth in the coming years due to its effective performance in boosting energy expenditure.
• Oral segment accounted for the largest market share owing to its convenience in taking medication.
• The hospitals segment is projected to experience a larger revenue share due to the presence of hospitals offering treatment for obese patients.
• Asia Pacific is projected to register the fastest growth during the forecast period, attributable to the increasing incidence of obesity.
• The global players include AstraZeneca, Aurobindo Pharma, Bausch Health Companies Inc., Cipla Inc., Currax Pharmaceuticals LLC, & Eisai Co., Ltd.

Polaris Market Research has segmented the anorexiants market report based on drug class, route of administration, end user and region:

Anorexiants, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

• Catecholamines
• Serotonin

Anorexiants, Route of Admission Outlook (Revenue - USD Million, 2019 - 2032)

• Oral
• Subcutaneous

Anorexiants, End User Outlook (Revenue - USD Million, 2019 - 2032)

• Institutional sales
• Hospitals
• Clinics
• Retail sales
• Online pharmacies
• Mail Order Pharmacies

Anorexiants, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of Asia Pacific

• Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa

Anorexiants Market Report Scope